Etzer Darout
Stock Analyst at Barclays
(4.57)
# 208
Out of 5,127 analysts
159
Total ratings
54.26%
Success rate
23.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Overweight | $115 → $116 | $100.05 | +15.94% | 2 | Feb 4, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $41 → $44 | $42.98 | +2.37% | 6 | Feb 4, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $8 → $10 | $5.53 | +80.83% | 14 | Feb 4, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $119 → $133 | $79.49 | +67.32% | 5 | Jan 28, 2026 | |
| RAPT RAPT Therapeutics | Downgrades: Equal-Weight | $58 | $57.74 | +0.45% | 4 | Jan 21, 2026 | |
| CRVS Corvus Pharmaceuticals | Maintains: Overweight | $16 → $28 | $19.58 | +43.00% | 2 | Jan 21, 2026 | |
| ANAB AnaptysBio | Maintains: Overweight | $55 → $78 | $50.24 | +55.25% | 4 | Jan 20, 2026 | |
| XNCR Xencor | Maintains: Overweight | $23 → $26 | $12.37 | +110.19% | 8 | Dec 17, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $45 → $52 | $47.64 | +9.15% | 8 | Dec 17, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $88 → $108 | $83.88 | +28.76% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $29 | $13.13 | +120.87% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $10 | $2.60 | +284.62% | 2 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $24 | $24.63 | -2.56% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $5 | $1.84 | +171.74% | 6 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $13.44 | +33.93% | 7 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $18 | $15.25 | +18.03% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $56 | $38.19 | +46.64% | 11 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $35 | $21.32 | +64.17% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $28 | $7.84 | +257.14% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $61 | $3.81 | +1,501.05% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $48 | $32.83 | +46.21% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $57.28 | +118.23% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $142 | $119.18 | +19.15% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $3 | $1.72 | +74.42% | 10 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $6.29 | +106.68% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $143 | $108.93 | +31.28% | 4 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $3.86 | -22.28% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $16.45 | +112.77% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $1.31 | +4,709.16% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.56 | +1,630.77% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $102.15 | +31.18% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $30.60 | +56.86% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $158.20 | -24.15% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.09 | +450.46% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $193.40 | -57.60% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $5.45 | +248.62% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $322.98 | -47.37% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $100.91 | -62.34% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $3.65 | +1,324.66% | 1 | Mar 28, 2018 |
Incyte
Feb 4, 2026
Maintains: Overweight
Price Target: $115 → $116
Current: $100.05
Upside: +15.94%
Exelixis
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $41 → $44
Current: $42.98
Upside: +2.37%
CytomX Therapeutics
Feb 4, 2026
Maintains: Overweight
Price Target: $8 → $10
Current: $5.53
Upside: +80.83%
Kymera Therapeutics
Jan 28, 2026
Maintains: Overweight
Price Target: $119 → $133
Current: $79.49
Upside: +67.32%
RAPT Therapeutics
Jan 21, 2026
Downgrades: Equal-Weight
Price Target: $58
Current: $57.74
Upside: +0.45%
Corvus Pharmaceuticals
Jan 21, 2026
Maintains: Overweight
Price Target: $16 → $28
Current: $19.58
Upside: +43.00%
AnaptysBio
Jan 20, 2026
Maintains: Overweight
Price Target: $55 → $78
Current: $50.24
Upside: +55.25%
Xencor
Dec 17, 2025
Maintains: Overweight
Price Target: $23 → $26
Current: $12.37
Upside: +110.19%
Scholar Rock Holding
Dec 17, 2025
Maintains: Overweight
Price Target: $45 → $52
Current: $47.64
Upside: +9.15%
Protagonist Therapeutics
Dec 17, 2025
Maintains: Overweight
Price Target: $88 → $108
Current: $83.88
Upside: +28.76%
Dec 17, 2025
Maintains: Overweight
Price Target: $48 → $29
Current: $13.13
Upside: +120.87%
Dec 17, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $2.60
Upside: +284.62%
Dec 17, 2025
Maintains: Underweight
Price Target: $21 → $24
Current: $24.63
Upside: -2.56%
Dec 17, 2025
Maintains: Overweight
Price Target: $10 → $5
Current: $1.84
Upside: +171.74%
Dec 17, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $13.44
Upside: +33.93%
Dec 17, 2025
Upgrades: Equal-Weight
Price Target: $16 → $18
Current: $15.25
Upside: +18.03%
Dec 9, 2025
Maintains: Overweight
Price Target: $36 → $56
Current: $38.19
Upside: +46.64%
Nov 24, 2025
Maintains: Overweight
Price Target: $22 → $35
Current: $21.32
Upside: +64.17%
Nov 24, 2025
Maintains: Overweight
Price Target: $11 → $28
Current: $7.84
Upside: +257.14%
Oct 13, 2025
Initiates: Overweight
Price Target: $61
Current: $3.81
Upside: +1,501.05%
Oct 13, 2025
Initiates: Overweight
Price Target: $48
Current: $32.83
Upside: +46.21%
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $57.28
Upside: +118.23%
Oct 13, 2025
Initiates: Overweight
Price Target: $142
Current: $119.18
Upside: +19.15%
Sep 17, 2025
Assumes: Overweight
Price Target: $3
Current: $1.72
Upside: +74.42%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $6.29
Upside: +106.68%
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $108.93
Upside: +31.28%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $3.86
Upside: -22.28%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $16.45
Upside: +112.77%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $1.31
Upside: +4,709.16%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.56
Upside: +1,630.77%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $102.15
Upside: +31.18%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $30.60
Upside: +56.86%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $158.20
Upside: -24.15%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.09
Upside: +450.46%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $193.40
Upside: -57.60%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $5.45
Upside: +248.62%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $322.98
Upside: -47.37%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $100.91
Upside: -62.34%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $3.65
Upside: +1,324.66%